Karyopharm Therapeutics Stock Target Price and Analyst Consensus

KPTI Stock  USD 7.25  0.70  8.81%   
The current analyst and expert consensus on Karyopharm Therapeutics is Strong Buy, with 2 strong buy opinions. The current projected Karyopharm Therapeutics target price consensus is 4.50 with 7 analyst opinions. Check out Macroaxis Advice on Karyopharm Therapeutics to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon.
For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.
The most common way Karyopharm Therapeutics analysts use to provide recommendation to the public is financial statements analysis. Many experts also interview Karyopharm Therapeutics executives and customers to further validate their buy or sell advice. Note, the total number of analysts currently providing their opinion is not significant to determine adequate consensus on Karyopharm Therapeutics. We strongly encourage you to use your own analysis of Karyopharm Therapeutics to validate this buy or sell advice. Karyopharm Therapeutics buy-or-sell recommendation module provides average expert sentiment on the projected Karyopharm Therapeutics target price to derive its highest and lowest estimates based on projected price volatility of 5.704.
Lowest Forecast
4.1
Highest Forecast
5
Target Price
4.5
As of now, Karyopharm Therapeutics' Gross Profit is increasing as compared to previous years. The Karyopharm Therapeutics' current Gross Profit Margin is estimated to increase to 1.01, while Pretax Profit Margin is projected to decrease to (0.55). As of now, Karyopharm Therapeutics' Net Debt is increasing as compared to previous years. The Karyopharm Therapeutics' current Cash is estimated to increase to about 99.3 M, while Total Stockholder Equity is forecasted to increase to (176.7 M).
  
It's important to approach Karyopharm Therapeutics' target price projections with caution. While they can be useful as part of a broader investment strategy, they are inherently speculative and subject to various kinds of risk, including market volatility and unforeseen external factors. Always consider multiple aspects and do your own research when making investment decisions.

Karyopharm Therapeutics Target Price Consensus

Karyopharm target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Karyopharm Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
   7  Strong Buy
Most Karyopharm analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Karyopharm stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Karyopharm Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice   Exposure   Valuation

Karyopharm Therapeutics Target Price Projection

Karyopharm Therapeutics' current and average target prices are 7.25 and 4.50, respectively. The current price of Karyopharm Therapeutics is the price at which Karyopharm Therapeutics is currently trading. On the other hand, Karyopharm Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.

Current Price

Karyopharm Therapeutics Market Quote on 3rd of March 2025

Low Price7.14Odds
High Price7.95Odds

7.25

Target Price

Analyst Consensus On Karyopharm Therapeutics Target Price

Low Estimate4.1Odds
High Estimate5.0Odds

4.5

Historical Lowest Forecast  4.1 Target Price  4.5 Highest Forecast  5.0
Note that most analysts generally publish their price targets in research reports on specific companies, along with recommendations for the company's stock.Although price targets are often quoted in the financial news media, there could be a delay between the publication of the latest analyst outlook on Karyopharm Therapeutics and the information provided on this page.

Karyopharm Therapeutics Analyst Ratings

Karyopharm Therapeutics' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Karyopharm Therapeutics stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Karyopharm Therapeutics' financials, market performance, and future outlook by experienced professionals. Karyopharm Therapeutics' historical ratings below, therefore, can serve as a valuable tool for investors.

Analyst Consensus Breakdown

Average Consensus Estimates

Analysts determine stock price targets through various methods, including financial modeling, peer comparison, and company analysis. The stock price target is the analyst's best estimate of the future price of a stock and is used by investors to make investment decisions. However, it is important to note that stock price targets are not guaranteed, and the actual price of a stock can differ significantly from the target due to various factors such as market conditions, economic events, and company developments.

Steps to utilize Karyopharm Therapeutics price targets

Karyopharm Therapeutics' stock target price is an estimate of its future price, usually made by analysts. Using Karyopharm Therapeutics' target price to determine if it is a suitable investment can be done through the following steps:
  • Look at Karyopharm Therapeutics' target prices provided by various analysts and compare them. This can help you gain a more balanced view of the Stock's potential.
  • Look at the analyst's track record to determine if they have a history of accurately predicting stock prices.
  • Look at the Company's financials, including revenue, earnings, and debt, to determine if it is in good financial health.
  • Consider market conditions. For example, take into account the state of the economy, competition, and regulatory environment, to determine if Karyopharm Therapeutics' stock is likely to perform well.
  • Diversify your portfolio and do not rely solely on stock target prices to make investment decisions. Invest in a mix of stocks, bonds, and other assets to manage risk.
Remember that stock target prices are just estimates and are subject to change. Therefore, using them as one factor in a larger investment strategy is essential rather than relying solely on them to make decisions.

Additional Karyopharm Therapeutics Value Projection Modules

Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of Karyopharm Therapeutics is a key component of Karyopharm Therapeutics valuation and have some predictive power on the future returns of a Karyopharm Therapeutics.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Karyopharm Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
1.827.4413.06
Details
Intrinsic
Valuation
LowRealHigh
0.245.8611.48
Details
Naive
Forecast
LowNextHigh
1.246.8612.47
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-4.39-3.98-3.6
Details

Trending Themes

If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment.
Hedge Favorites Idea
Hedge Favorites
Invested few shares
Investor Favorites Idea
Investor Favorites
Invested over 30 shares
Momentum Idea
Momentum
Invested over 60 shares
Banking Idea
Banking
Invested over 30 shares
Corona Opportunity Idea
Corona Opportunity
Invested few shares
Dividend Beast Idea
Dividend Beast
Invested over 60 shares
Artificial Intelligence Idea
Artificial Intelligence
Invested few shares
Automobiles and Trucks Idea
Automobiles and Trucks
Invested over 300 shares
Manufacturing Idea
Manufacturing
Invested over 30 shares
ESG Investing Idea
ESG Investing
Invested few shares
Driverless Cars Idea
Driverless Cars
Invested over 20 shares
When determining whether Karyopharm Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Karyopharm Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Karyopharm Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Karyopharm Therapeutics Stock:
Check out Macroaxis Advice on Karyopharm Therapeutics to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon.
For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.
You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.